338 related articles for article (PubMed ID: 8765523)
1. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.
Bergmann KE; Cynamon MH; Welch JT
J Med Chem; 1996 Aug; 39(17):3394-400. PubMed ID: 8765523
[TBL] [Abstract][Full Text] [Related]
2. Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity.
Cynamon MH; Gimi R; Gyenes F; Sharpe CA; Bergmann KE; Han HJ; Gregor LB; Rapolu R; Luciano G; Welch JT
J Med Chem; 1995 Sep; 38(20):3902-7. PubMed ID: 7562923
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives.
Seitz LE; Suling WJ; Reynolds RC
J Med Chem; 2002 Dec; 45(25):5604-6. PubMed ID: 12459027
[TBL] [Abstract][Full Text] [Related]
4. Antimycobacterial activity of a series of pyrazinoic acid esters.
Cynamon MH; Klemens SP; Chou TS; Gimi RH; Welch JT
J Med Chem; 1992 Apr; 35(7):1212-5. PubMed ID: 1560435
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and antimycobacterial evaluation of N-substituted 3-aminopyrazine-2,5-dicarbonitriles.
Zitko J; Jampílek J; Dobrovolný L; Svobodová M; Kuneš J; Doležal M
Bioorg Med Chem Lett; 2012 Feb; 22(4):1598-601. PubMed ID: 22281187
[TBL] [Abstract][Full Text] [Related]
6. [In vitro antimycobacterial activities of pyrazinamide analogs: results of screening tests].
Yamamoto S; Toida I; Watanabe N; Ura T
Kekkaku; 1996 Mar; 71(3):253-8. PubMed ID: 8901227
[TBL] [Abstract][Full Text] [Related]
7. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.
Simões MF; Valente E; Gómez MJ; Anes E; Constantino L
Eur J Pharm Sci; 2009 Jun; 37(3-4):257-63. PubMed ID: 19491013
[TBL] [Abstract][Full Text] [Related]
8. Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.
Pires D; Valente E; Simões MF; Carmo N; Testa B; Constantino L; Anes E
Antimicrob Agents Chemother; 2015 Dec; 59(12):7693-9. PubMed ID: 26438493
[TBL] [Abstract][Full Text] [Related]
9. Relationship between the structure and antimycobacterial activity of substituted salicylanilides.
Waisser K; Bures O; Holý P; Kunes J; Oswald R; Jirásková L; Pour M; Klimesová V; Kubicová L; Kaustová J
Arch Pharm (Weinheim); 2003 Mar; 336(1):53-71. PubMed ID: 12666254
[TBL] [Abstract][Full Text] [Related]
10. QSAR modeling of a set of pyrazinoate esters as antituberculosis prodrugs.
Fernandes JP; Pasqualoto KF; Felli VM; Ferreira EI; Brandt CA
Arch Pharm (Weinheim); 2010 Feb; 343(2):91-7. PubMed ID: 20099263
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, antimycobacterial and antifungal evaluation of 3-arylaminopyrazine-2,5-dicarbonitriles.
Palek L; Dvorák J; Svobodová M; Buchta V; Jampílek J; Dolezal M
Arch Pharm (Weinheim); 2008 Jan; 341(1):61-5. PubMed ID: 18072243
[TBL] [Abstract][Full Text] [Related]
12. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
Zimhony O; Vilchèze C; Arai M; Welch JT; Jacobs WR
Antimicrob Agents Chemother; 2007 Feb; 51(2):752-4. PubMed ID: 17101678
[TBL] [Abstract][Full Text] [Related]
13. Salicylanilide pyrazinoates inhibit in vitro multidrug-resistant Mycobacterium tuberculosis strains, atypical mycobacteria and isocitrate lyase.
Krátký M; Vinšová J; Novotná E; Stolaříková J
Eur J Pharm Sci; 2014 Mar; 53():1-9. PubMed ID: 24333643
[TBL] [Abstract][Full Text] [Related]
14. Iron enhances the antituberculous activity of pyrazinamide.
Somoskovi A; Wade MM; Sun Z; Zhang Y
J Antimicrob Chemother; 2004 Feb; 53(2):192-6. PubMed ID: 14729751
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and antimycobacterial properties of N-substituted 6-amino-5-cyanopyrazine-2-carboxamides.
Zitko J; Dolezal M; Svobodova M; Vejsova M; Kunes J; Kucera R; Jilek P
Bioorg Med Chem; 2011 Feb; 19(4):1471-6. PubMed ID: 21273083
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antimycobacterial evaluation of pyrazinamide derivatives with benzylamino substitution.
Zitko J; Paterová P; Kubíček V; Mandíková J; Trejtnar F; Kuneš J; Doležal M
Bioorg Med Chem Lett; 2013 Jan; 23(2):476-9. PubMed ID: 23237840
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides.
Rai D; Johar M; Srivastav NC; Manning T; Agrawal B; Kunimoto DY; Kumar R
J Med Chem; 2007 Sep; 50(19):4766-74. PubMed ID: 17696514
[TBL] [Abstract][Full Text] [Related]
18. N-benzylsalicylthioamides: highly active potential antituberculotics.
Dolezal R; Waisser K; Petrlíková E; Kunes J; Kubicová L; Machácek M; Kaustová J; Dahse HM
Arch Pharm (Weinheim); 2009 Feb; 342(2):113-9. PubMed ID: 19137534
[TBL] [Abstract][Full Text] [Related]
19. New agents with antimycobacterial activity.
Marco-Contelles J; Gómez-Sánchez E
Arch Pharm (Weinheim); 2005 Nov; 338(11):562-3. PubMed ID: 16281303
[TBL] [Abstract][Full Text] [Related]
20. In vitro and ex vivo activity of new derivatives of acetohydroxyacid synthase inhibitors against Mycobacterium tuberculosis and non-tuberculous mycobacteria.
Sohn H; Lee KS; Ko YK; Ryu JW; Woo JC; Koo DW; Shin SJ; Ahn SJ; Shin AR; Song CH; Jo EK; Park JK; Kim HJ
Int J Antimicrob Agents; 2008 Jun; 31(6):567-71. PubMed ID: 18337064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
